CPT code 77750 represents an intratumoral or intracavitary infusion/instillation of a radioelement solution intended to destroy tumor cells. The code is notable because it bundles hospital admission and a defined three-month postoperative follow-up period into a single procedural code, which has implications for facility billing, episode-based accounting, and care coordination. Nationally, this code applies to specialized oncology and interventional radiology services delivered in hospital settings and affects reimbursement workflows for complex oncologic interventions.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical intent and service context, payer coverage considerations, common modifiers, and the potential operational impacts of a bundled admission plus follow-up period. The publication outlines benchmarking approaches, coding and billing nuances, and clinical context for use of intratumoral radioelement therapy. Where specific payer policy detail or claim-level benchmarks are required, the report indicates whether those data were available; items not provided in the input are noted as "Data not available in the input."